VicapSys Life Sciences Inc. (VICP)

Overview

Vicapsys Life Sciences, Inc., originally known as Phage Therapeutics International, Inc., underwent a name change in September 2017 to better reflect its focused efforts in the life sciences sector. The company, established in 1997, is headquartered in Cumming, Georgia. It is dedicated to the development and commercialization of innovative solutions in the field of transplantation and related therapies. Vicapsys Life Sciences leverages cutting-edge biotechnology to create products that address the critical needs in transplantation therapies, stem-cell applications, and wound healing, marking its commitment to advancing healthcare and improving patient outcomes.

Products and Services

• VICAPSYN

This proprietary product by Vicapsys Life Sciences is targeted at transplantation therapies and related stem-cell applications. VICAPSYN is designed to enhance the effectiveness and efficiency of transplantation procedures, thereby offering improved treatment options for patients undergoing such therapies. Its development represents a significant step forward in the company's mission to address the challenges faced in the transplantation field.

• VYBRIN

VYBRIN is another innovative product developed by Vicapsys, based on the molecule CXCL12. It serves multiple purposes in the medical field, including the prevention of post-surgical adhesions in abdominal surgery, a common complication that can lead to significant patient discomfort and additional medical procedures. Additionally, VYBRIN is formulated to coat implantable medical devices and other implants to eliminate fibrosis, thus reducing the risk of implant rejection and enhancing the overall success rate of such medical interventions. Furthermore, its application extends to wound healing, with a particular focus on diabetic ulcers, offering hope for improved healing processes in patients suffering from diabetes-related complications.